<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137997">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075281</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EXC-205</org_study_id>
    <nct_id>NCT02075281</nct_id>
  </id_info>
  <brief_title>Effect of LAPS-Exendin on Body Weight in Obese Population</brief_title>
  <official_title>A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal dose and regimen of HM11260C, in
      combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise
      considered in stable health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2 study
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in body weight at 20 weeks</measure>
    <time_frame>20 weeks from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse event</measure>
    <time_frame>during 20 weeks of treatment and follow-up period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c and fasting plasma glucose level at 20 week</measure>
    <time_frame>20 weeks from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week</measure>
    <time_frame>20 weeks from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cholesterol level, LDL-C level</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in waist circumference at 20 week</measure>
    <time_frame>20 weeks after baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Î²-cell function at 20 week</measure>
    <time_frame>20 week from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>homeostatic model assessment</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>HM11260C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 4 mg weekly sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo weekly sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C 6 mg/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 6 mg weekly sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C 6 mg/biweekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 6 mg biweekly sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C 8 mg/biweekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 8 mg biweekly sc injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>Glucagon-like peptide-1 analogue</description>
    <arm_group_label>HM11260C</arm_group_label>
    <arm_group_label>HM11260C 6 mg/week</arm_group_label>
    <arm_group_label>HM11260C 6 mg/biweekly</arm_group_label>
    <arm_group_label>HM11260C 8 mg/biweekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               -  Age: 18 years to 65 years

               -  Genders: male and female

               -  healthy obese population

               -  non-diabetes

               -  stable body weight for at least 3 months prior to screening

          2. Exclusion Criteria

               -  Pregnant or nursing (lactating) women

               -  Drug-induced obesity

               -  Diabetes mellitus (type 1, 2, and other)

               -  Previous surgical treatment for obesity

               -  Any known history of severe gastrointestinal (GI) disease or intolerance

               -  Known history of pancreatitis with presence of raised serum amylase and lipase

               -  History of suicide attempts or recent history (within 2 years prior to
                  screening) of major depression, anxiety, or other psychiatric disease requiring
                  treatment with prescription medication including selective serotonin reuptake
                  inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor s (SNRIs),
                  antipsychotics, and lithium.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi pharmaceuticals Hanmi pharmaceuticals</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanmi pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanmi Pharmaceutical Hanmi pharmaceutical</last_name>
    <phone>clinicl4@hanmi.co.kr</phone>
    <email>clinicl4@hanmi.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanmi Pharmaceutical Hanmi pharmaceutical</last_name>
    <email>clinicl4@hanmi.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanmi pharmaceutical</name>
      <address>
        <city>Los angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanmi pharmaceutical Hanmi pharmaceutical</last_name>
      <email>clinicl4@hanmi.co.kr</email>
    </contact>
    <investigator>
      <last_name>Hanmi pharmaceutical Hanmi pharmaceutical</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
